Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha

Gene Therapy
R A MarrF L Graham

Abstract

The most limiting factor regarding the use of TNF alpha in tumour therapy is systemic toxicity. The expression of membrane-bound (nonsecreted) TNF alpha within a tumour may serve to reduce systemic toxicity while retaining anti-tumour activity. Two adenovirus (Ad) vectors were constructed: (1) Ad-mTNF-wt expressing wild-type murine TNF alpha; and (2) Ad-mTNF-MEM expressing a mutant non-secreted (membrane-bound) form. Only the Ad-mTNF-wt vector induced high levels of TNF alpha secretion in transduced cells (approximately 400 ng/10(6) cells), however, both vectors induced efficient cell surface expression as detected by FACS. These vectors were used in tumour immunotherapy trials in a murine transgenic breast cancer model. High serum concentrations of mTNF alpha (approximately 1 ng/ml) were detected only in Ad-mTNF-wt-treated mice, while both vectors induced substantial disruption of tumour pathology. The wt TNF vector was highly toxic, killing 12 of 16 mice at a dose of 5 x 10(8) p.f.u., whereas the Ad-mTNF-MEM vector showed low toxicity killing three of 27 at the same dose. Both vectors induced partial, and in some cases, permanent tumour regressions, with cured mice displaying protective immunity and specific CTL activity agai...Continue Reading

Citations

Oct 2, 2001·Critical Reviews in Oncology/hematology·P M McLaughlinL F de Leij
Nov 5, 2002·Critical Reviews in Oncology/hematology·A H KlimpT Daemen
Jul 31, 2002·Seminars in Cancer Biology·Ron N Apte, Elena Voronov
Feb 16, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Wen-Yu PanMi-Hua Tao
Jan 19, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·K M el-ShamiL Eisenbach
Apr 29, 1998·The Journal of Clinical Investigation·X F LeiM Jordana
Jun 21, 2014·Future Oncology·Meaghan L KhanMitesh J Borad
Dec 22, 2015·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Elena Voronov, Ron N Apte
Mar 28, 2008·Immunological Reviews·Ron N Apte, Elena Voronov
May 16, 2008·Medicinal Research Reviews·Tian-Lu Cheng, Steve Roffler
Feb 17, 2010·Immune Network·Young Sang Kim
Jan 1, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xin HuZhuoya Li
May 9, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S GyorffyJ Gauldie
Dec 13, 2016·BMC Biotechnology·Anam Qudrat, Kevin Truong
May 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S JodoS T Ju
Dec 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xiaoping SongRon N Apte
Jun 25, 2013·Cancer Research·Mingxia YuZhuoya Li
Jun 12, 2002·The American Journal of Pathology·Peter J MargettsJack Gauldie

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.